IceCure launches U.S. post‑marketing study to validate cryoablation for low‑risk breast cancer
Executive summary: IceCure Medical initiated the ChoICE post‑marketing study at the West Cancer Center & Research Institute to assess ProSense® cryoablation for low‑risk breast cancer. The study will provide clinical data that may influence reimbursement policies and increase uptake of cryoablation as a breast‑cancer treatment option.
Who is involved: IceCure Medical (Nasdaq: ICCM), West Cancer Center & Research Institute, patients with low‑risk breast cancer.
Likely next: Enrollment of patients will proceed, with interim data expected in 2027 and full study results anticipated by the end of the decade.
IceCure Medical announced the start of its ChoICE post‑marketing study at the West Cancer Center & Research Institute, marking the first U.S. clinical site for evaluating its ProSense® cryoablation system in low‑risk breast cancer patients. The study aims to generate real‑world evidence that could support broader reimbursement and clinical adoption of the minimally invasive technology. This move follows IceCure’s recent expansion of its U.S. commercial team to address growing demand for its tumor‑ablation platform.
What's next — scenarios
Successful Clinical Validation (50%)
IceCure secures standard-of-care status for low-risk breast cancer, driving rapid US market penetration.
- Positive interim safety data from West Cancer Center
- High enrollment rate in ChoICE study
Regulatory & Reimbursement Friction (30%)
Commercial expansion stalls as slow insurance coverage limits physician adoption despite study progress.
- Lack of new reimbursement codes
- Delay in study milestone reporting
Limited Clinical Utility (20%)
The technology is relegated to a niche second-line option rather than a primary minimally invasive alternative.
- Comparative efficacy data shows non-inferiority issues versus traditional surgery
- Low physician interest reported in expansion regions
What to watch
- Enrollment milestones for the ChoICE study (next 60 days)
- Quarterly commercial headcount updates from IceCure (next 90 days)
- Announcements regarding US insurance coverage/coding status (next 90 days)
Timeline
- — IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site (PR Newswire)
Analysis — what this means
Sectors affected
- low-risk breast cancer cryoablation treatment market
Historical parallels
- IceCure expanded its U.S. commercial team on July 14, 2026 to meet surging demand for ProSense® cryoablation